secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revance Therapeutics, Inc. (—)
CIK:        0001479290
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001479290-24-000034
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revance Q4 product revenue $58.5M (+28%); guides 2024 at least $280M
--------------------------------------------------------------------

- Q4 product revenue $58.5M (DAXXIFY $24M, RHA $34.5M); full year product $212.7M (+80% YoY).
- 2024 product revenue guidance at least $280M; DAXXIFY cervical dystonia launch mid-year.
- GAAP net loss FY 2023 $324M; Adjusted EBITDA loss $160.1M; cash $253.9M as of Dec 31.
- President Dustin Sjuts steps down effective March 31; separation includes 18 months base salary.
- OPUL payments business exit by Q1 2024, generating ~$20M annual savings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/0001479290-24-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479290/000147929024000034/rvnc-20240223.htm
  HTML page:      https://secwatch.observer/filing/0001479290-24-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer